Prognostic impact of immunophenotyping of diffuse large B-cell lymphoma - a single-centre experience
-
Published:2021
Issue:1
Volume:67
Page:43-54
-
ISSN:1857-8969
-
Container-title:Macedonian Pharmaceutical Bulletin
-
language:en
-
Short-container-title:Maced. Pharm. Bull.
Author:
Trajkova Sanja1, Krstevska-Balkanov Svetlana1, Petrusevska Gordana2, Cevreska Lidija1, Pivkova-Veljanovska Aleksandra1, Popova-Labacevska Marija1, Ridova Nevenka1, Stojanovska Simona1, Panovska-Stavridis Irina1
Affiliation:
1. University Clinic for Hematology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, Mother Theresa 17, 1000 Skopje, Republic of North Macedonia 2. Institute of Pathology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, 50 Divizija 6, 1000 Skopje, Republic of North Macedonia
Abstract
The concept generated by biological expression profile divided patients with diffuse large B-cell lymphoma (DLBCL) into two subtypes. This concept has been presented in the recent editions of WHO classification and became a prognostic tool. Aim of the study was introduction of new three-marker model for immunohistochemical and prognostic subclasification of patients with DLBCL. Our retrospective study enrolled 200 adult patients with DLBCL diagnosed and treated in the period between January 2013 to January 2021. They were all treated with chemoimmunotherapy with R+/-CHOP regimen and the median follow-up of the patients was 48 months. We analysed the biopsy samples immunohistochemically with the markers of germinal (BCL6) and post-germinal centre (MUM1), and the marker of apoptosis (BCL2).
Using the immunohistochemical three-marker model, which consisted of BCL-2, BCL-6, and MUM1, we distributed the patients with DLBCL into 2 subgroups: germinal centre – like (GCL) and activated centre-like lymphoma (ACL). The GCL and ACL patients were comparable regarding age, gender and all other already established prognostic parameters. Patients with GCL had overall survival of 140 months, and patients with ACL had overall survival of 88 months. ACL patients with BCL2 expression had a shorter survival compared to ACL patients without BCL2 expression. The difference in survival was statistically significant for p=0.01914.
The study introduced the new three-marker model for immunohistochemical subclasification of patients with DLBCL treated with immunochemotherapy. Apoptotic marker BCL2 is a strong survival predictor. In the present study, we confirmed the prognostic importance of BCL2 protein expression, which showed a predictive capacity in ACL.
Keywords: DLBCL, three - marker model, immunohistochemical, BCL2
Publisher
Macedonian Pharmaceutical Association
Reference20 articles.
1. Armitage, J.O., Gascoyne, R.D., Lunning, M.A., Cavalli, F., 2017. Non-Hodgkin lymphoma. Lancet 390(10091), 298-310. Available at: https://doi.org/10.1016/S0140-6736(16)32407-2. 2. Artiga, M.J., Sáez, A.I., Romero, C., Sánchez-Beato, M., Mateo, M.S., Navas, C., Mollejo, M., Piris, M.A., 2002. A short mutational hot spot in the first intron of BCL-6 is associated with increased BCL-6 expression and with longer overall survival in large B-cell lymphomas. Am. J. Pathol. 160(4), 1371-1380. Available at: https://doi.prg/10.1016/S0002-9440(10)62564-3. 3. Braaten, K.M., Betensky, R.A., De Leval, L., Okada, Y., Hochberg, F.H., Louis, D.N., Harris, N.L., Batchelor, T.T., 2003. BCL-6 Expression Predicts Improved Survival in Patients with Primary Central Nervous System Lymphoma. Clin. Canc. Res. 9(3), 1063-1069. Available at: https://doi.org/10.1158/1078-0432.CCR-21-0066. 4. Colomo, L., López-Guillermo, A., Perales M., Rives, S., Martínez, A., Bosch, F., Colomer, D., Falini, B., Montserrat, E., Campo, E., 2003. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 101(1), 78-84. Available at: https://doi.org/10.1182/blood-2002-04-1286. 5. Danial, N.N., Korsmeyer, S.J., 2004. Cell death: critical control points. Cell 116(2), 205-19. Available at: https://doi.org/10.1016/s0092-8674(04)00046-7.
|
|